R.A. FAYZULLINA, K.A. SAFINA

Kazan State Medical University of the Ministry of Health of the Russian Federation, Kazan

 Contact:

Fayzullina R.A. ― MD, Professor, Head of the Department of Propedeutics of Children’s Diseases and Polyclinical Pediatrics

Address: 49 Butlerov Str., Kazan, Russian Federation, 420012, e-mail: r868@mail.ru

 The wide prevalence of cardiovascular diseases encourages scientists to constantly search for a solution of this problem. Progress in studying intestinal microbiota has allowed a new look at the state of a human body and its diseases. This review describes contemporary views on the intestinal microbiota composition effect on the pathogenesis and course of cardiovascular diseases. These data suggest that intestinal microbiome functions as an endocrine organ, producing biologically active metabolites that can directly or indirectly affect the host’s physiology. It was found that trimethylamine metabolite, short-chain fatty acids and second bile acids probably play a role in the occurrence and progression of atherosclerosis, arterial hypertension, coronary heart disease and heart failure. It was experimentally proved that taking probiotics prevents blood pressure rises. Considering intenstinal microbiota as a therapeutic target will give rise to new research and development of potential strategies for the prevention and treatment of cardiovascular diseases.

Key words: intestinal microbiota, cardiovascular diseases, coronary heart disease, atherosclerosis, heart failure.

(For citation: Fayzullina R.A., Safina K.A. Role of intestinal microbiota in cardiovascular diseases. Practical medicine. 2020. Vol. 18, №1, P. 54-59)

REFERENCES

1. New opportunities for reducing cardiovascular risk in the Russian Federation (post-release): materials of the XIV National Congress of Therapists. Russkiy meditsinskiy zhurnal, 2019, no. 12, pp. 14-16 (in Russ.).
2. Informatsiya o sotsial’no-ekonomicheskom polozhenii Rossii [Information on the socio-economic situation of Russia]. Federal’naya sluzhba gosudarstvennoy statistiki. Moscow, 2019. Pp. 116-117.
3. Epidemiology of cardiovascular diseases in various regions of Russia (Essay-RF). The rationale and design of the study. Scientific and Organizational Research Committee ESSE-RF. Profilakticheskaya meditsina, 2013, no. 6, pp. 25-26 (in Russ.).
4. Lityaeva L.A., Kovaleva O.V. The role of nutrition and intestinal microbiota of a pregnant woman in programming the health of a child. Detskie infektsii, 2017, no. 16 (2), pp. 40-44 (in Russ.).
5. Desbonnet L., Clarke G., O’Sullivan O., Crispie F. et al. Gut microbiota depletion from early adolescence in mice: implications for brain and behavior. Brain, Behavior, and Immunity, 2015, vol. 48, pp. 165-173.
6. Kumar Ganesan, Sookja Kim Chung et al. Causal Relationship between Diet-Induced Gut Microbiota Changes and Diabetes: A Novel Strategy to Transplant Faecalibacterium prausnitzii in Preventing Diabetes. International Journal of Molecular Sciences, 2018, vol. 19 (12), p. 3720.
7. Kelly J.R., Minuto C. et al. Cross Talk: The Microbiota and Neurodevelopmental Disorders. Front Neurosci, 2017, vol. 11, p. 490.
8. Jing Lu, Sylvia Synowiec et al. Microbiota influence the development of the brain and behaviors in C57BL/6J mice. PLoS One, 2018, vol. 13 (8), available at: https://www.ncbi.nlm.nih.gov/pubmed/30075011
9. Marie-Claire Arrieta, Leah T. Stiemsma et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Science Translational Medicine, 2015, vol. 7 (307), p. 307ra152, available at: https://www.ncbi.nlm.nih.gov/pubmed/26424567
10. Gholizadeh P., Mahallei M. et al. Microbial balance in the intestinal normal microbiome and its association with diabetes, obesity and allergic disease. Microbial Pathogenesis, 2018, available at: https://www.researchgate.net/publication/329293502_Microbial_balance_in_the_intestinal_normal_microbiome_and_its_association_with_diabetes_obesity_and_allergic_disease
11. Méndez-Salazar E.O., Ortiz-López M.G. et al. Altered Gut Microbiota and Compositional Changes in Firmicutes and Proteobacteria in Mexican Undernourished and Obese Children. Frontiers in Microbiology, 2018, vol. 9, pp. 2494-2503.
12. Kozhevnikov A.A. et al. Intestinal microbiota: modern ideas about the species composition, functions and research methods. Russkiy meditsinskiy zhurnal, 2017, no. 17 (09), pp. 1244-1247 (in Russ.).
13. Yadav M., Verma M.K., Chauhan N.S. A review of metabolic potential of human gut microbiome in human nutrition. Arch. Microbiol, 2018, vol. 200 (2), pp. 203-217.
14. Asano Y., Hiramoto T., Nishimo R. et al. Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice. Am. J. Physiol. Gastrointest. Liver Physiol, 2012, vol. 303, pp. 1288-1295.
15. Levy M., Thaiss C.A., Elinav E. et al. Metabolites: Messengers between the microbiota and the immune system. Genes Dev, 2016, vol. 30, pp. 1589-1597. http://genesdev.cshlp.org/content/30/14/1589
16. Pieczynska M.D., Yang Y. et al. Gut Microbiota and Its Metabolites in Atherosclerosis Development. Molecules, 2020, vol. 25 (3), p. 594.
17. Jin M., Qian Z., Yin J., Xu W. The role of intestinal microbiota in cardiovascular disease. J. Cell Mol Med, 2019, vol. 23 (4), pp. 2343-2350.
18. Mente A., Chalcraft K., Ak H. et al. The Relationship Between Trimethylamine-N-Oxide and Prevalent Cardiovascular Disease in a Multiethnic Population Living in Canada. The Canadian journal of cardiology, 2015, vol. 31 (9), pp. 1189-1194.
19. Nowiński A., Ufnal M. Trimethylamine N-oxide: A harmful, protective or diagnostic marker in lifestyle diseases? Nutrition, 2018, vol. 46, pp. 7-12.
20. Drapkina O.M., Shirobokikh O.E. The role of intestinal microbiota in the pathogenesis of cardiovascular diseases and metabolic syndrome. Ratsional’naya farmakoterapiya v kardiologii, 2018, vol. 14 (4), pp. 567-574 (in Russ.).
21. Ahmadmehrabi S., Tang W.H., Gut W. Microbiome and its role in cardiovascular diseases. Current Opinion in Cardiology, 2017, vol. 32 (6), pp. 761-766.
22. Anders H.J., Andersen K., Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney International, 2013, vol. 83, no. 6, pp. 1010-1016.
23. Liu Z., Li J., Liu H., Tang Y. The intestinal microbiota associated with cardiac valve calcification differs from that of coronary artery disease. Atherosclerosis, 2019, vol. 284, pp. 121-128.
24. Chen M., Yi L., Zhang Y. Resveratrol attenuates trimethylamine-N-oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota. and others. mBio, 2016, vol. 7 (2), pp. 2210-2215.
25. Din A.U., Hassan A., Zhu Y. et al. Amelioration of TMAO through probiotics and its potential role in atherosclerosis. Applied Microbiology and Biotechnology, 2019, vol. 103 (23-24), pp. 9217-9228.
26. Yang S., Li X., Yang F. et al. Gut Microbiota-Dependent Marker TMAO in Promoting Cardiovascular Disease: Inflammation Mechanism, Clinical Prognostic, and Potential as a Therapeutic Target. Front. Pharmacol, 2019, vol. 10, pp. 1360-1371.
27. Janeiro M.H., Ramírez M.J., Milagro F.I. et al. Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target. Nutrients, 2018, vol. 10 (10), pp. 1398-1413.
28. Millar C.L., Jiang C., Norris G.H. et al. Cow’s milk polar lipids reduce atherogenic lipoprotein cholesterol, modulate gut microbiota and attenuate atherosclerosis development in LDL-receptor knockout mice fed a Western-type diet. J. Nutr. Biochem, 2020, vol. 79, pp. 108351.
29. Antony S., de Leon M.P. Probiotics and its relationships with the cardiovascular system. Intech Open, 2018.
30. Yoshida N., Emoto T., Yamashita T. et al. Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis. Circulation, 2018, vol. 138 (22), pp. 2486-2498.
31. Xie J., Lu W., Zhong L. et al. Alterations in gut microbiota of abdominal aortic aneurysm mice. BMC Cardiovascular Disorders, 2020, vol. 20, p. 32.
32. Shikata F., Shimada K., Sato H. et al. Potential Influences of Gut Microbiota on the Formation of Intracranial Aneurysm. Hypertension, 2019, vol. 73 (2), rr. 491-496.
33. Richards E.M., Pepine C.J., Raizada M.K., Kim S. The Gut, Its Microbiome, and Hypertension. Curr. Hypertens Rep, 2017, vol. 19 (4), pp. 36-44.
34. Robles-Vera I., Toral M., de la Visitación N. et al. Probiotics Prevent Dysbiosis and the Rise in Blood Pressure in Genetic Hypertension: Role of Short-Chain Fatty Acids. Mol Nutr. Food Res, 2020. https://doi.org/10.1002/mnfr.201900616
35. Katsimichas T., Antonopoulos A.S., Katsimichas A. et al. The intestinal microbiota and cardiovascular disease. Cardiovascular Research, 2019. DOI: 10.1093/cvr/cvz135
36. Ganesh B.P., Nelson J.W., Eskew J.R. et al. Prebiotics, Probiotics, and Acetate Supplementation Prevent Hypertension in a Model of Obstructive Sleep Apnea. Hypertension, 2018, vol. 72 (5), pp. 1141-1150.
37. Yang T., Santisteban M.M., Rodriguez V. Gut microbiota dysbiosis is linked to hypertension. Hypertension, 2015, vol. 65 (6), pp. 1331-1340.
38. Vasquez E.C., Pereira T.M.C. et al. Probiotics as Beneficial Dietary Supplements to Prevent and Treat Cardiovascular Diseases: Uncovering Their Impact on Oxidative Stress. Oxidative Medicine and Cellular Longevity, vol. 2019, 3 p.
39. Robles-Vera I., Toral M., Romero M. et al. Antihypertensive Effects of Probiotics. Curr Hypertens Rep, 2017, vol. 19 (4), pp. 26-35.
40. Durgan D.J. Obstructive Sleep Apnea-Induced Hypertension: Role of the Gut Microbiota. Curr Hypertens Rep, 2017, vol. 19 (4), pp. 35-43.
41. Albenberg L., Esipova T.V., Judge C.P., et al. Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota. Gastroenterology, 2014, vol. 147 (5), pp. 1055-1063.
42. Mashaqi, Gozal. Obstructive Sleep Apnea and Systemic Hypertension: Gut Dysbiosis as the Mediator? Journal of Clinical Sleep Medicine, 20, vol. 15, no. 10, pp. 1517-1527.
43. Tang T.V.H., Chen H-C., Chen C-Y. et al. Loss of gut microbiota alters immune system composition and cripples postinfarction cardiac repair. Circulation, 2019, 139, pp. 647-659.
44. Lam V., Su J., Koprowski S., Hsu A. et al. Intestinal microbiota determine severity of myocardial infarction in rats. Faseb J, 2012, 26, pp. 1727-1735.
45. Zununi Valed S., Barsegari A., Zuluaga M. et al. Myocardial infarction and gut microbiota: An incidental connection. Pharmacol. Res, 2018, Mar, 129, pp. 308-317.
46. Branchereau M., Burcelin R., Heymes C. The gutmicrobiome and heart failure: A better gut for a better heart. Rev. Endocr. Metab. Disord, 2019, Vol. 20 (4), pp. 407-414.
47. Zhu Q., Gao R., Zhang Y.et al. Dysbiosis signatures of gut microbiota in coronary artery disease. Physiol Genomics, 2018, vol. 50 (10), pp. 893-903.
48. Amin A.M., Mostafa H., Arif N.H. et al. Metabolomics profiling and pathway analysis of human plasma and urine reveal further insights into the multifactorial nature of coronary artery disease. Clin. Chim. Acta, 2019, vol. 493, pp. 112-122.
49. Liu H., Chen X., Hu X. et al. Alterations in the gutmicrobiome and metabolism with coronary artery disease severity. Microbiome, 2019, vol. 7 (1), pp. 68-74.
50. Malik M., Suboc T.M., Tyagi S. et al. Lactobacillus plantarum 299v Supplementation Improves Vascular Endothelial Function and Reduces Inflammatory Biomarkers in Men With Stable Coronary Artery Disease. Circulation Research, 2018, vol. 123 (9), pp. 1091-1102.
51. Horvath A., Leber B., Feldbacher N. et al. Effects of a multispecies synbiotic on glucose metabolism, lipid marker, gut microbiome composition, gut permeability, and quality of life in diabesity: a randomized, double-blind, placebo-controlled pilot study. European Journal of Nutrition, 2019. https://doi.org/10.1007/s00394-019-02135-w
52. Mayerhofer C.C.K., Kummen M., Holm K. et al. Low fibre intake is associated with gut microbiota alterations in chronic heart failure. ESC Heart Fail, 2020. https://onlinelibrary.wiley.com/doi/full/10.1002/ehf2.12596.
53. Kitai T., Kirsop J., Tang W.H. Exploring the Microbiome in Heart Failure. Heart Fail Rep, 2016, vol. 13 (2), pp. 103-109.
54. Tang W.W.H., Li D.Y., Hazen S.L. Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol, 2019, vol. 16 (3), pp. 137-154.
55. Liu Z., Liu X.Y., Zhou H. et al. Moderate-Intensity Exercise Affects Gut Microbiome Composition and Influences Cardiac Function in Myocardial Infarction Mice. Front. Microbiol, 2017, vol. 8, p. 1687.
56. Felizardo R.J.F., Watanabe I.K.M., Dardi P. et al. The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids and others. Pharmacol Res, 2019, vol. 141, pp. 366-377.
57. Kain V., Van Der Pol W., Mariappan N. et al. Obesogenic diet in aging mice disrupts gut microbe composition and alters neutrophil: lymphocyte ratio, leading to inflamed milieu in acute heart failure. FASEB J, 2019, vol. 33 (5), pp. 6456-6469.
58. Lataro R.M., Imori P.F.M., Santos E.S. et al. Heart failure developed after myocardial infarction does not affect gut microbiota composition in the rat. Physiol Gastrointest Liver Physiol, 2019, vol. 317 (3), pp. 342-348.